Kamada Ltd
NASDAQ:KMDA
Kamada Ltd
NASDAQ:KMDA
Price:
8.24
USD
-2.37%
Market Closed
Market Cap:
$475.3m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Popular Picks
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Kamada Ltd
EPS (Diluted)
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
Kamada Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kamada Ltd
NASDAQ:KMDA
|
EPS (Diluted)
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
EPS (Diluted)
$0
|
CAGR 3-Years
29%
|
CAGR 5-Years
4%
|
CAGR 10-Years
35%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
EPS (Diluted)
-$3
|
CAGR 3-Years
13%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
EPS (Diluted)
$0
|
CAGR 3-Years
-12%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
EPS (Diluted)
-$2
|
CAGR 3-Years
29%
|
CAGR 5-Years
24%
|
CAGR 10-Years
19%
|
|
|
M
|
Matricelf Ltd
TASE:MTLF
|
EPS (Diluted)
₪0
|
CAGR 3-Years
10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
No Stocks Found
Kamada Ltd
Glance View
Kamada Ltd. engages in the development and production of pharmaceutical products. The firm uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
KMDA
Intrinsic Value
8.32
USD
Undervaluation 1%
See Also
What is Kamada Ltd's EPS (Diluted)?
EPS (Diluted)
0.4
USD
0.4
USD
Based on the financial report for Dec 31, 2025, Kamada Ltd's EPS (Diluted) amounts to 0.4 USD.
What is Kamada Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-2%
-2%
Over the last year, the EPS (Diluted) growth was 40%.
